Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 39 | 2023 | 5097 | 1.670 |
Why?
|
| Tuberculosis | 13 | 2023 | 543 | 1.340 |
Why?
|
| Anti-HIV Agents | 18 | 2022 | 1324 | 1.320 |
Why?
|
| Isoniazid | 9 | 2023 | 110 | 0.880 |
Why?
|
| HIV-1 | 16 | 2022 | 1260 | 0.760 |
Why?
|
| AIDS-Related Opportunistic Infections | 7 | 2021 | 195 | 0.740 |
Why?
|
| Antitubercular Agents | 9 | 2023 | 322 | 0.730 |
Why?
|
| HIV Protease Inhibitors | 6 | 2022 | 92 | 0.670 |
Why?
|
| Adult | 39 | 2023 | 5913 | 0.660 |
Why?
|
| Lopinavir | 7 | 2019 | 137 | 0.650 |
Why?
|
| CD4 Lymphocyte Count | 21 | 2021 | 656 | 0.640 |
Why?
|
| Benzoxazines | 6 | 2022 | 123 | 0.630 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2019 | 118 | 0.620 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 299 | 0.620 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2023 | 324 | 0.610 |
Why?
|
| Rifampin | 9 | 2023 | 197 | 0.600 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2023 | 226 | 0.580 |
Why?
|
| Male | 35 | 2023 | 6754 | 0.580 |
Why?
|
| Humans | 47 | 2023 | 14537 | 0.570 |
Why?
|
| Ritonavir | 7 | 2022 | 137 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 13 | 2018 | 472 | 0.550 |
Why?
|
| Female | 39 | 2023 | 9103 | 0.530 |
Why?
|
| Viral Load | 11 | 2022 | 819 | 0.470 |
Why?
|
| Anti-Retroviral Agents | 9 | 2022 | 551 | 0.460 |
Why?
|
| Immune Tolerance | 1 | 2013 | 22 | 0.450 |
Why?
|
| Primary Care Nursing | 1 | 2012 | 2 | 0.410 |
Why?
|
| Nevirapine | 4 | 2022 | 146 | 0.400 |
Why?
|
| Raltegravir Potassium | 5 | 2022 | 14 | 0.380 |
Why?
|
| Latent Tuberculosis | 2 | 2023 | 45 | 0.370 |
Why?
|
| Drug Therapy, Combination | 11 | 2023 | 279 | 0.360 |
Why?
|
| Alkynes | 6 | 2022 | 117 | 0.330 |
Why?
|
| Cyclopropanes | 6 | 2022 | 123 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2023 | 329 | 0.310 |
Why?
|
| Tenofovir | 6 | 2020 | 171 | 0.300 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.290 |
Why?
|
| Cohort Studies | 9 | 2021 | 967 | 0.290 |
Why?
|
| Treatment Outcome | 10 | 2021 | 889 | 0.260 |
Why?
|
| Middle Aged | 15 | 2021 | 3601 | 0.260 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2018 | 256 | 0.230 |
Why?
|
| HIV Seropositivity | 2 | 2019 | 265 | 0.220 |
Why?
|
| South Africa | 18 | 2021 | 7596 | 0.220 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 1422 | 0.200 |
Why?
|
| Young Adult | 11 | 2021 | 2498 | 0.200 |
Why?
|
| Risk Factors | 7 | 2023 | 1475 | 0.190 |
Why?
|
| Incidence | 6 | 2023 | 685 | 0.190 |
Why?
|
| Nitriles | 3 | 2022 | 27 | 0.190 |
Why?
|
| Pyrimidines | 3 | 2022 | 32 | 0.190 |
Why?
|
| Cervical Intraepithelial Neoplasia | 2 | 2012 | 36 | 0.190 |
Why?
|
| Adolescent | 9 | 2023 | 2985 | 0.180 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 171 | 0.180 |
Why?
|
| Antibodies, Bacterial | 1 | 2022 | 153 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 14 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 231 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 62 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2012 | 115 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 69 | 0.160 |
Why?
|
| Streptococcus pneumoniae | 1 | 2022 | 336 | 0.160 |
Why?
|
| Contraception Behavior | 2 | 2010 | 54 | 0.160 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 278 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 276 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2021 | 799 | 0.160 |
Why?
|
| Circumcision, Male | 1 | 2019 | 99 | 0.160 |
Why?
|
| Drug Resistance, Viral | 4 | 2019 | 278 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 12 | 0.150 |
Why?
|
| Lamivudine | 3 | 2016 | 89 | 0.150 |
Why?
|
| Organophosphonates | 3 | 2015 | 45 | 0.150 |
Why?
|
| Plasma | 1 | 2018 | 39 | 0.150 |
Why?
|
| AIDS Vaccines | 1 | 2019 | 152 | 0.150 |
Why?
|
| Adenine | 3 | 2015 | 91 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2018 | 55 | 0.140 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2016 | 8 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2019 | 1160 | 0.140 |
Why?
|
| Mass Screening | 1 | 2018 | 245 | 0.140 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 196 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 106 | 0.130 |
Why?
|
| Body Composition | 1 | 2016 | 153 | 0.120 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2015 | 33 | 0.120 |
Why?
|
| Zidovudine | 2 | 2012 | 59 | 0.120 |
Why?
|
| Family Characteristics | 3 | 2020 | 135 | 0.120 |
Why?
|
| Risk | 1 | 2013 | 87 | 0.110 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 6 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2011 | 120 | 0.110 |
Why?
|
| Program Evaluation | 2 | 2010 | 89 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2012 | 8 | 0.100 |
Why?
|
| Dideoxynucleosides | 1 | 2012 | 29 | 0.100 |
Why?
|
| Developing Countries | 3 | 2019 | 400 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 74 | 0.100 |
Why?
|
| Sexual Behavior | 2 | 2010 | 320 | 0.090 |
Why?
|
| Tuberculin Test | 2 | 2023 | 49 | 0.090 |
Why?
|
| Darunavir | 2 | 2022 | 12 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 41 | 0.090 |
Why?
|
| Thinness | 1 | 2010 | 18 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 187 | 0.090 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cyclohexanes | 1 | 2010 | 5 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 156 | 0.090 |
Why?
|
| Triazoles | 1 | 2010 | 20 | 0.090 |
Why?
|
| Menstruation Disturbances | 1 | 2010 | 7 | 0.090 |
Why?
|
| Viremia | 1 | 2010 | 66 | 0.090 |
Why?
|
| Hospitalization | 1 | 2013 | 418 | 0.090 |
Why?
|
| Menstruation | 1 | 2010 | 10 | 0.090 |
Why?
|
| Emtricitabine | 3 | 2016 | 78 | 0.090 |
Why?
|
| Patient Preference | 1 | 2010 | 30 | 0.080 |
Why?
|
| Community Health Services | 1 | 2009 | 58 | 0.080 |
Why?
|
| Urban Health Services | 1 | 2009 | 10 | 0.080 |
Why?
|
| Fertility | 1 | 2009 | 22 | 0.080 |
Why?
|
| Intention | 1 | 2009 | 23 | 0.080 |
Why?
|
| Decision Making | 1 | 2009 | 53 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2010 | 321 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2009 | 325 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2015 | 272 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2009 | 167 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2020 | 133 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2011 | 175 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 171 | 0.070 |
Why?
|
| Linear Models | 2 | 2019 | 83 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2010 | 529 | 0.060 |
Why?
|
| Medication Adherence | 2 | 2019 | 151 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2015 | 12 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 2 | 2016 | 125 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 135 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2015 | 303 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 435 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 5 | 0.050 |
Why?
|
| Metabolome | 1 | 2021 | 2 | 0.050 |
Why?
|
| Chemokines | 1 | 2021 | 9 | 0.050 |
Why?
|
| Thailand | 1 | 2021 | 26 | 0.050 |
Why?
|
| Disease Progression | 2 | 2012 | 154 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 48 | 0.050 |
Why?
|
| India | 1 | 2021 | 62 | 0.050 |
Why?
|
| Nigeria | 1 | 2021 | 49 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2012 | 42 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 20 | 0.050 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2021 | 10 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2021 | 34 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 31 | 0.040 |
Why?
|
| Statistical Distributions | 1 | 2020 | 2 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 1748 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 370 | 0.040 |
Why?
|
| Urban Population | 2 | 2013 | 257 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2019 | 50 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 25 | 0.040 |
Why?
|
| Biomarkers | 1 | 2021 | 327 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 227 | 0.040 |
Why?
|
| Ethambutol | 1 | 2019 | 9 | 0.040 |
Why?
|
| Pyridazines | 1 | 2019 | 6 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 480 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 96 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 33 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 188 | 0.040 |
Why?
|
| Pyrazinamide | 1 | 2019 | 14 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 101 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 49 | 0.040 |
Why?
|
| Condoms | 1 | 2019 | 88 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 411 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 36 | 0.040 |
Why?
|
| Child | 2 | 2018 | 2242 | 0.040 |
Why?
|
| Focus Groups | 2 | 2010 | 196 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 18 | 0.040 |
Why?
|
| Logistic Models | 1 | 2018 | 254 | 0.040 |
Why?
|
| Rural Population | 2 | 2013 | 654 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 262 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 253 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 85 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 50 | 0.030 |
Why?
|
| Aged | 2 | 2011 | 1740 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 21 | 0.030 |
Why?
|
| Secondary Care | 1 | 2015 | 1 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 127 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1192 | 0.030 |
Why?
|
| Pregnancy | 2 | 2010 | 1862 | 0.030 |
Why?
|
| Nucleotides | 1 | 2013 | 1 | 0.030 |
Why?
|
| Nucleosides | 1 | 2013 | 3 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2012 | 8 | 0.030 |
Why?
|
| Death | 1 | 2012 | 14 | 0.030 |
Why?
|
| Rilpivirine | 1 | 2012 | 7 | 0.030 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2012 | 41 | 0.020 |
Why?
|
| African Americans | 1 | 2012 | 47 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 100 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 151 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 10 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 376 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 38 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 24 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 306 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2011 | 34 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 105 | 0.020 |
Why?
|
| Self Report | 1 | 2011 | 114 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2010 | 9 | 0.020 |
Why?
|
| Amenorrhea | 1 | 2010 | 9 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 121 | 0.020 |
Why?
|
| Culture | 1 | 2010 | 23 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 149 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2010 | 13 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 54 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2009 | 64 | 0.020 |
Why?
|
| Quality of Life | 1 | 2011 | 177 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2010 | 111 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 221 | 0.020 |
Why?
|
| Women's Health | 1 | 2009 | 41 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 563 | 0.020 |
Why?
|
| Laboratories | 1 | 2009 | 47 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 127 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2010 | 215 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2010 | 240 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 203 | 0.020 |
Why?
|
| Health Promotion | 1 | 2009 | 109 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2009 | 321 | 0.020 |
Why?
|
| Health Personnel | 1 | 2009 | 231 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 280 | 0.020 |
Why?
|
| Obesity | 1 | 2010 | 367 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2010 | 472 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 2244 | 0.010 |
Why?
|